FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower…
I'm taking 10 mg of zolpidem — given the FDA's lower recommended starting dose for women and slower metabolizers, should I be on 5 mg instead?
Well-supported by good-quality research. how we score evidence
In January 2013 the FDA halved the recommended starting dose of zolpidem for women (10 mg to 5 mg immediate-release; 12.5 mg to 6.25 mg extended-release) because next-morning blood levels can remain high enough to impair driving and alertness.
Worth asking
I'm taking 10 mg of zolpidem — given the FDA's lower recommended starting dose for women and slower metabolizers, should I be on 5 mg instead?
What it is FDA approved for
Read off the label. Trial duration and approval year are shown only where they were recorded — never inferred.
- Short-term treatment of insomnia characterized by difficulties with sleep initiation
Source
FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem — US Food and Drug Administration (2013)
Regulator or national health body
How this was scored
- Study design
- Regulatory safety determination
- Funding
- No external funding
- Published in
- Regulator or national health body
- Sample size
- not recorded
- Preregistered
- No
- Conflicts disclosed
- No
- Independent of proponent
- Yes
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published August 19, 2026.
Questions
How strong is the evidence behind this?
Resolv rates this source "strong evidence". Well-supported by good-quality research. It scores 82 out of 100 on our published rubric. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem — US Food and Drug Administration (2013). Published in: Regulator or national health body. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Regulatory safety determination. Funding: No external funding. The researchers were independent of whoever benefits from the result. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is zolpidem (Ambien, Edluar, Intermezzo), ambien, edluar, intermezzo FDA approved?
Yes — FDA approved for Short-term treatment of insomnia characterized by difficulties with sleep initiation. Approval is for a specific indication, not for everything the drug is prescribed for.
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.